{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-24-000099","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.750125+00:00","generated_at":"2026-06-01T06:51:55.176151+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcus reports Phase 2 EDGE-Gastric interim data: median PFS 12.9 months, ORR 58.5% in upper GI cancers","bullets":["Median PFS of 12.9 months (95% CI 9.8–13.8) across 41 patients in the domvanalimab+zimberelimab+chemo arm.","Confirmed ORR 58.5%, with 3 complete responses and median DOR of 12.4 months (95% CI 9.9–NE).","PD-L1-high subgroup (TAP ≥5%) showed median PFS 13.8 months and ORR 68.8% (n=16).","No unexpected safety signals; infusion-related reactions in 19.5% of subjects, mostly chemotherapy-related.","Data cutoff March 12, 2024; results posted to company website on June 2, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-24-000099","json":"https://secwatch.observer/filing/0001724521-24-000099.json","markdown":"https://secwatch.observer/filing/0001724521-24-000099.md","text":"https://secwatch.observer/filing/0001724521-24-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000099/0001724521-24-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000099/rcus-20240602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:51:55.176151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}